Mitochondrial Diseases

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-04-15
EMA Authorised: Kygevvi (doxecitine;Doxribtimine) — UCB Pharma
The EMA authorized Kygevvi (doxecitine; Doxribtimine) from UCB Pharma for mitochondrial diseases, with orphan medicine designation.